50 likes | 149 Views
XMRV status determined by the WPI since the submission to Science . WPI Repository CFS Subjects with Cancer. XMRV status determined by the WPI since the submission to Science. 1988- seen at NIH for CFS 1998- Splenectomy to decrease aggressiveness.
E N D
XMRV status determined by the WPI since the submission to Science. WPI Repository CFS Subjects with Cancer XMRV status determined by the WPI since the submission to Science.
1988- seen at NIH for CFS 1998- Splenectomy to decrease aggressiveness. 2000- seen at NIH for mantle cell lymphoma. Given Rituxan and Velcade 2004- BMT with adult stem cells 2008- Blast crisis MCL…. death WPI-1125 CFS Diagnosis One Decade Prior to MCL • 1988---Seen at NIH for CFS • 1998---Splenectomy to decrease aggressiveness. • 2000---Seen at NIH for mantle cell lymphoma. Given Rituxan and Velcade • 2004---BMT with adult stem cells • 2008---Blast crisis MCL … death MCL cell line developed 2008
Relationship between RNaseL variant genotype and XMRV expression in CFS patients Neither XMRV infection nor a diagnosis of CFS correlate to RNase L genetic variation R462Q
Dysfunction of Natural Killer Activity in a Family with Chronic Fatigue Syndrome
Relative time-scale of the virological and immunological events during XMRV infection Hypothesis of XMRV disease progression: NK dysregulation Relative time-scale of the virological and immunological events during XMRV infection CFS develops Env antigen